Booming antibodies 2001
MasterControl - Learn How to Avoid Obstacles in Pharma Manufacturing
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!

Pharma Press Releases

Keep up to date with the latest technological developments happening across the Pharmaceutical industry. Our press releases can help you boost your online reach and exposure worldwide. Our Press releases provides information on the latest research in pharma.

AbbVie and Cugene Announce Collaboration in Autoimmune Diseases

Monday, May 16, 2022

AbbVie and Cugene Inc a clinicalstage biotechnology company focused on developing nextgeneration precision immunology and oncology medicines to treat autoimmune disease and cancer today announced an exclusive worldwide license option agreement for CU...

Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages

Monday, May 16, 2022

Emergent BioSolutions Inc announced today that it has entered into a definitive agreement with Chimerix Inc to acquire Chimerixs exclusive worldwide rights to TEMBEXA brincidofovir the first antiviral approved by the US Food and Drug Administration F...

Athenex Announces Clinical Collaboration with Merck to Evaluate Oraxol plus KEYTRUDA® (pembrolizumab) in Patients with Non-Small Cell Lung Cancer (NSCLC)

Monday, May 16, 2022

Athenex Inc a global biopharmaceutical company dedicated to the discovery development and commercialization of novel therapies for the treatment of cancer and related conditions today announced a clinical trial collaboration and supply agreement with...

ScPharmaceuticals Inc. Announces FDA Acceptance of FUROSCIX® New Drug Application

Monday, May 16, 2022

ScPharmaceuticals Inc a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies advance patient care and reduce healthcare costs today announced that the Companys...

Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy

Monday, May 16, 2022

Travere Therapeutics Inc announced the US Food and Drug Administration FDA has accepted and granted Priority Review of its New Drug Application NDA under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy IgAN The F...

Crown Bioscience and MBL Enter Joint Venture to Provide Advanced Preclinical Services for Japanese Customers

Thursday, May 12, 2022

Crown Bioscience and Medical Biological Laboratories MBL JSR Life Sciences companies today announced the formation of a joint venture to further expand the provision of Crown Biosciences preclinical services to Japanese customers The new entity name...

Roche enters partnership with the Global Fund to support low- and middle-income countries in strengthening critical diagnostics infrastructure

Thursday, May 12, 2022

Roche through its Global Access Program and The Global Fund to Fight AIDS Tuberculosis and Malaria are joining forces to build and strengthen diagnostic capacity and pandemic preparedness in lowand middleincome countries fighting against HIV and tube...

Sun Pharma Announces US FDA Approval for Generic Mesalamine Extended Release Capsules

Thursday, May 12, 2022

Sun Pharmaceutical Industries Limited today announced that it has received final approval from US FDA for its Abbreviated New Drug Application ANDA for generic Mesalamine Extended Release Capsules mg The generic product approval is based on Pentasa...

Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Beta Thalassemia

Thursday, May 12, 2022

Editas Medicine Inc a leading genome editing company today announced that the US Food and Drug Administration FDA granted Orphan Drug Designation to EDIT an investigational gene editing medicine for the treatment of beta thalassemia The FDA previousl...

Skye Bioscience Signs Arrangement Agreement with Emerald Health Therapeutics

Thursday, May 12, 2022

Skye Bioscience Inc and Emerald Health Therapeutics Inc announced today that the companies have entered into a definitive agreement with respect to a transaction to be completed by way of a Plan of Arrangement the Arrangement whereby Skye would acqui...

BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology

Thursday, May 12, 2022

BridgeBio Pharma Inc a commercialstage biopharmaceutical company focused on genetic diseases and cancers announced today an exclusive license with Bristol Myers Squibb to develop and commercialize BBP a potentially bestinclass SHP inhibitor in oncolo...

FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19

Wednesday, May 11, 2022

Eli Lilly and Company and Incyte announced today the US Food and Drug Administration FDA has approved OLUMIANT baricitinib for the treatment of COVID in hospitalized adults requiring supplemental oxygen noninvasive or invasive mechanical ventilation...

ArisGlobal Acquires Boehringer Ingelheim’s Signal Analytics Engine, Bringing Enhanced and Unmatched Pharmacovigilance Capabilities to Life Sciences Industry

Wednesday, May 11, 2022

ArisGlobal the global market leader in drug safety solutions worldwide and Boehringer Ingelheim a leading researchdriven biopharmaceutical company today announced the acquisition of Boehringer Ingelheims digital innovation BRASS by ArisGlobal This da...

Cue Biopharma Receives FDA Acceptance of Investigational New Drug (IND) Application for CUE-102 in Wilms’ Tumor 1 (WT1) - expressing cancers

Wednesday, May 11, 2022

Cue Biopharma Inc a clinicalstage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patients body today announced that the US Food and Drug Administratio...

Neuronetics and Transformations Care Network Announce Extended Commercial Partnership

Wednesday, May 11, 2022

Neuronetics Inc a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need it with the best neurohealth therapies in the world today announced an extended commercial par...

Avantor® and Cytovance Biologics Collaborate to Accelerate Plasmid DNA Development for Biopharma Customers

Tuesday, May 10, 2022

Avantor Inc a leading global provider of missioncritical products and services to customers in the life sciences advanced technologies and applied materials industries and Cytovance Biologics Inc a biologics contract development and manufacturing org...

Lonza and ALSA Ventures Collaborate to Provide Development and Manufacturing Services for Biotech Firms

Tuesday, May 10, 2022

ALSA Ventures a London based European biotech investment firm and Lonza a global development and manufacturing partner to the pharma biotech and nutrition industries announced today a framework collaboration agreement to help ALSAs portfolio of precl...

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Tuesday, May 10, 2022

Flagship Pioneering and Novo Nordisk AS today announced a collaboration to create a portfolio of novel research programmes to develop transformational medicines The companies will explore opportunities to apply Flagships innovative bioplatforms an e...

Castle Biosciences Collaborates with The Sun Bus to Provide Free Skin Cancer Screenings

Tuesday, May 10, 2022

Castle Biosciences Inc a company improving health through innovative tests that guide patient care today announced that for the second year it is a national sponsor of The Sun Bus a mobile clinic that provides free skin checks and sun safety educatio...

SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields New Patent Application for Psychedelic Combination Treatment for Binge Behaviors

Tuesday, May 10, 2022

SciSparc Ltd a specialty clinicalstage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system today announced that its recently launched collaboration with Clearmind Medicine Inc a pharmaceuti...

Eiger BioPharmaceuticals and AnGes Announce Exclusive Partnership for Regulatory Approval and Commercialization of Zokinvy® (lonafarnib) in Japan

Tuesday, May 10, 2022

Eiger Biopharmaceuticals Inc and AnGes Inc announced that the companies entered into an agreement for the regulatory approval marketing and distribution of Zokinvy lonafarnib for the treatment of HutchinsonGilford progeria syndrome HGPS or progeria a...

Tetra Bio-Pharma Announces Licensing Agreement with True North for Patented CBD Technology

Tuesday, May 10, 2022

Tetra BioPharma Inc a leader in cannabinoidderived drug discovery and development in collaboration with Panag a subsidiary of Tetra BioPharma and True North Cannabis Corp True North today announced it has entered into a technology licensing agreement...

Cumberland Pharmaceuticals Announces Key Co-Promotion Agreement with Verity Pharmaceuticals to Expand Support for Sancuso®

Monday, May 09, 2022

Specialty pharmaceutical company Cumberland Pharmaceuticals Inc announced today that it has entered into a national copromotion agreement with Verity Pharmaceuticals International Ltd to support Cumberlands new Sancuso oncology support product Sancus...

Acer Therapeutics Announces Agreement with FDA on Special Protocol Assessment for its Phase 3 EDSIVO™ (celiprolol) Trial in Vascular Ehlers-Danlos Syndrome Patients

Monday, May 09, 2022

Acer Therapeutics Inc a pharmaceutical company focused on the acquisition development and commercialization of therapies for serious rare and lifethreatening diseases with significant unmet medical needs today announced it has reached agreement with...

Twist Bioscience Enters into Research, Exclusive Option and License Agreement with Astellas for Antibodies to Reduce Tumor Microenvironment-Mediated Immunosuppression

Monday, May 09, 2022

Twist Bioscience Corporation a company enabling customers to succeed through its offering of highquality synthetic DNA using its silicon platform today announced it has entered into a research collaboration and exclusive option license agreement with...

Novartis receives European Commission approval for Jakavi® to be the first post-steroid treatment for acute and chronic graft-versus-host disease

Thursday, May 05, 2022

Novartis today announced the European Commission EC has approved Jakavi ruxolitinib for the treatment of patients aged years and older with acute or chronic GvHD who have inadequate response to corticosteroids or other systemic therapies Today of p...

Prime Therapeutics is acquiring Magellan Rx to advance integrated specialty drug management, accelerating efforts to lower the cost of drugs and improve health outcomes

Thursday, May 05, 2022

Pharmacy benefit manager Prime Therapeutics LLC Prime on May entered into a definitive agreement with Centene Corporation to acquire Magellan Health Incs pharmacy business Magellan Rx Management Magellan Rx for approximately billion This is a timel...

Nabriva Extends Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S. Through the End of 2026

Thursday, May 05, 2022

Nabriva Therapeutics plc a biopharmaceutical company engaged in the commercialization and development of innovative antiinfective agents to treat serious infections today announced that it agreed to an extension of its exclusive agreement with subsid...

Societal CDMO Signs Three-Year Manufacturing and Supply Agreement With InfectoPharm for Ritalin LA® in Europe

Thursday, May 05, 2022

Societal CDMO Inc a contract development and manufacturing organization CDMO dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development today announced that it has entered into a threeyea...

Rousselot® Biomedical announces the launch of Quali-Pure HGP 2000

Wednesday, May 04, 2022

Rousselot Darling Ingredients health brand and the global leader of collagenbased solutions launches QualiPure HGP a new endotoxincontrolled pharmaceuticalgrade gelatin specifically designed for vaccines and wound healing applications As the latest...

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEA Bora Pharmaceuticals - CMDO making success Medical Fair Asia 2022 Medical Manufacturing Asia 2022